NASDAQ:HZNP
Delisted

Horizon Therapeutics Public Company Stock News

etoro logo Buy HZNP
*Your capital is at risk
$116.30
+0 (+0%)
At Close: Jan 04, 2024
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P; 500 Index wa
If you're interested in Horizon Therapeutics Public Limited Company (NASDAQ:HZNP), then you might want to consider its...
Amalgamated Bank boosted its stake in shares of Horizon Therapeutics PLC (NASDAQ:HZNP) by 11.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Excha
Credit Suisse AG grew its holdings in shares of Horizon Therapeutics PLC (NASDAQ:HZNP) by 23.8% during the 4th quarter, HoldingsChannel reports. The firm owned 182,649 shares of the biopharmaceutical
Horizon Therapeutics PLC:
Tim Walbert has been the CEO of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) since 2008. This analysis...
Wall Street analysts expect that Horizon Therapeutics PLC (NASDAQ:HZNP) will report sales of $288.18 million for the current quarter, according to Zacks Investment Research. Two analysts have made est
Darzalex is a major revenue driver for Genmab. The company may start earning significant revenues from other approved products as well as from pipeline products
Equities analysts expect Horizon Therapeutics PLC (NASDAQ:HZNP) to report earnings per share (EPS) of $0.22 for the current quarter, according to Zacks. Two analysts have provided estimates for Horizo
Envestnet Asset Management Inc. lifted its stake in Horizon Therapeutics PLC (NASDAQ:HZNP) by 28.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Excha
2020 already looks promising for this profitable specialty pharma company despite global markets melting down.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE